| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_26eadf98e8514d2595b19e6fb6c0ffd2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02f24694b4445e31254823f04656311e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D455-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 |
| filingDate |
2006-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed0f2861df4a36aef5b2ceb781827938
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e7963c8f85586c0492c17beab2cabb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_345ffdea913dd1cd159263e96a742e66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3cc94fcd0da21374fda034b5cd88982
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46cce7d121386234beb50d06e4f4720c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e76c5b5e013f53eac654be0164f29299
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cee78c3a8c0ea88ebce7bfd5839cfb95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de9eaac79f856c8cd3adbc9a770214ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e73d521052e06865cea05e97afaf75ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c3ed2321bf1aba3f05b83a5e533298b |
| publicationDate |
2009-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009149488-A1 |
| titleOfInvention |
Tetrahydroprotoberberine Compounds, the Synthetic Method and the Use Thereof |
| abstract |
The present invention relates to tetrahydroprotoberberines of the formula (I) and the physiologically acceptable salts thereof. The invention also relates to the use of the compounds of the formula (I) or pharmaceutically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with dopamine receptor ligand, such as schizophrenia. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11731965-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2704257-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020530483-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7100693-B2 |
| priorityDate |
2005-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |